For many young scientists, a PhD is the start of an international career.The result is obvious: a prestigious research fellowship, a postdoctoral position abroad, publications in leading journals and, finally, a faculty position.Dr. Parul Ganju he had that chance.He received his PhD in Skin Biology from the National Institute of Immunology (NII), New Delhi. He had a research relationship with the government that he could reach. A postdoctoral position in the United States was also on the table.But during his doctoral research, something happened that changed his definition of success.He began meeting people with vitiligo, a chronic disease in which the body’s immune system destroys pigment-producing cells, leaving white spots on the skin. In India, where appearance often affects confidence, relationships and job opportunities, they discovered that the disease affects more than skin.
Why Dr. Parul Ganju turned down an offer in the United States to receive treatment for vitiligo. (Photo: LinkedIn)
“The results of the disease were funny,” he later recalled. “People were waiting for something to work.”That question stayed with him long after his PhD.Instead of asking where his work would take him, he began to ask other questions.Who actually arrested the girl?
When patients changed the instructions for the work of the scientist
Dr. Ganju had spent years studying the biology of the skin, but interacting with patients gave him a new purpose.He realized that despite the advances in science over the years, there were few ways to treat vitiligo.Commonly prescribed drugs, especially steroids, often suppress the immune system to reduce the risk of infection. Although they can help some patients, they do not stop the disease forever, they cannot restore lost color in many cases and they can cause serious problems when used for a long time.For the millions of people with vitiligo, there was no treatment that directly affected the cause of the disease.Instead of accepting this, he decided to change.
He left a good job to create a biotech startup
In 2016, Dr Parul Ganju founded Ahammune Biosciences in Pune with his PhD colleague Dr Krishnamurthy Natarajan, a professor at Jawaharlal Nehru University (JNU).It was an unacceptable decision.Building a biotech company meant years of uncertainty, fundraising, failed experiments and long clinical trials.However, he believed that publishing another research paper would not immediately change a patient’s life.Drug development maybe.The lead drug, AB1001, was designed to work differently than existing drugs.Instead of suppressing the immune system too much, it aims to block the cellular signaling pathway that destroys melanocytes – the pigment-producing cells involved in vitiligo.Dr. Ganju has described this method simply as “cutting wood for fire.”Today, AB1001 has successfully completed Phase 1 clinical trials and has advanced to Phase 2, bringing it one step closer to becoming a new treatment option.The company has also acquired patents in several countries and raised around 8 million US dollars from investors including pi Ventures, Ideaspring Capital and Kotak Alternate Assets.
Why is his story important? World Allergy Day
Today, July 8, is observed around the world as World Allergy Daya reminder of the growing complexity of the immune system and the need to advance research into immune-mediated processes.Although vitiligo is not known as an allergy, it is an autoimmune disease, where the body’s immune system mistakenly attacks healthy cells in the body.The event provides an opportunity to recognize scientists who are working to better understand immune system diseases and develop treatments that change the lives of patients.It also relates to a larger message of interest through things like National Love Your Skin Day – healthy skin is about more than appearance. It’s about confidence, having a good life and living a good life.
Sometimes the biggest career decision isn’t about where you go – it’s about why you live
For students, the visit of Dr. Parul Ganju offers a different way of thinking about success.Many graduates dream of foreign research positions, prestigious fellowships and international careers.There is nothing wrong with those desires.But his story shows that sometimes the biggest impact comes from choosing a difficult path—one driven by purpose rather than fame.Millions of people around the world continue to suffer from vitiligo, with India having one of the highest rates.Whether AB1001 will eventually become a widely available treatment will depend on the results of ongoing clinical trials and regulatory approval.But one thing is already known.A scientist who ended his career in paper printing decided to use it to solve a problem that patients have had for years.And sometimes, it’s the kind of research that changes lives.Disclaimer: This article is based on publicly available information about Dr. Parul Ganju, Ahammune Biosciences and the company’s ongoing drug research. AB1001’s documentation is relevant to the growing medical field. The drug is still under investigation and has not yet received approval for clinical use. This article is for informational and educational purposes only and should not be considered medical advice.